Leeward Financial Partners LLC Invests $888,000 in Adaptive Biotechnologies Corporation $ADPT

Leeward Financial Partners LLC bought a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 41,400 shares of the company’s stock, valued at approximately $888,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd acquired a new stake in Adaptive Biotechnologies in the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC increased its holdings in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares during the last quarter. KBC Group NV acquired a new position in shares of Adaptive Biotechnologies during the 1st quarter worth approximately $45,000. Assetmark Inc. raised its stake in Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in Adaptive Biotechnologies during the 4th quarter valued at $51,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $24.74 on Friday. The stock has a fifty day moving average price of $21.28 and a 200-day moving average price of $17.12. The company has a market cap of $3.95 billion, a price-to-earnings ratio of -60.34 and a beta of 2.08. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. Adaptive Biotechnologies Corporation has a fifty-two week low of $11.92 and a fifty-two week high of $26.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The company had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business’s revenue for the quarter was up 21.5% compared to the same quarter last year. During the same period last year, the company posted ($0.17) earnings per share. As a group, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current fiscal year.

Insider Activity

In other news, insider Sharon Benzeno sold 154,768 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $21.14, for a total value of $3,271,795.52. Following the completion of the transaction, the insider directly owned 221,278 shares in the company, valued at approximately $4,677,816.92. The trade was a 41.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 492,400 shares of the company’s stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the sale, the insider directly owned 812,058 shares of the company’s stock, valued at approximately $17,775,949.62. This trade represents a 37.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,310,086 shares of company stock valued at $27,934,739. Corporate insiders own 5.70% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on ADPT shares. Guggenheim raised their target price on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. cut their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. TD Cowen upped their target price on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Morgan Stanley lifted their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average price target of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.